Allergan's Short-Lived Botox Alternative Boey
A new short-duration neurotoxin aims to attract first-time users, while a review finds CeraVe's vitamin C lotion underwhelming for brightening.

The skincare and aesthetics landscape sees developments in both high-tech injectables and accessible topical treatments. A new, short-lived botulinum toxin called Boey is poised to lower the barrier for first-time users, while a detailed review questions the efficacy of CeraVe's latest brightening lotion.
A Short-Lived Neurotoxin
Allergan, the pharmaceutical giant behind Botox, has developed a new short-duration neurotoxin called Boey, approved by the European Commission earlier this year. The product uses a type E botulinum toxin, which works in as little as eight hours and lasts only two to three weeks, compared to the days-long onset and three to four month duration of traditional type A toxins. Aesthetic doctor Dr. Alicia Gonzalez-Fernandez explains that the product is built for people curious about injectables but nervous about committing to a long-lasting result.
While awaiting separate UK approval, practitioners anticipate Boey will attract a new demographic. Experts suggest it could be cheaper than longer-acting toxins, further enticing a younger generation, though current Botox costs in the UK range from £150 to £350 per syringe. The primary target includes people in their thirties and forties who have contemplated treatment for years, as well as men who are often more cautious about visible changes. The temporary nature also appeals for use around specific events, a concept one potential user described as intentional for key life moments without ongoing upkeep.
Despite the potential for wider adoption, some practitioners express skepticism about its revolutionary impact. Dr. Gonzalez-Fernandez notes that a common concern among her existing patients is Botox not lasting long enough, with many opting for longer-lasting versions despite higher cost. The product's marketing as a low-commitment option risks making beauty maintenance routines more expensive. The underlying commercial strategy appears focused on converting first-timers into lifelong customers who may spend between £600 and over £1200 annually on maintenance.
CeraVe's Brightening Lotion Review
A recent review of the CeraVe Brightening Vitamin C Lotion, updated in October 2026, gave the product a three out of five rating. The fragrance-free moisturiser is formulated with niacinamide, ceramides, and the vitamin C derivative ascorbyl glucoside, promising to hydrate skin and fade dark spots.
The reviewer found the lotion to be a decent moisturiser that leaves skin soft and smooth, but criticized its sticky texture and tendency to pill. More significantly, the product delivered disappointing results for its core brightening claim, with dark spots showing little improvement. The review concluded it might be worth buying for hydration but not for treating pigmentation.
The key brightening agent, niacinamide, is a form of vitamin B3 known to help fade hyperpigmentation by inhibiting melanin transfer, with potential results in as little as four weeks. The formula also contains three types of ceramides (NP, AP, and EOP) plus cholesterol, which work together to strengthen the skin's barrier and improve hydration. However, the efficacy of the included vitamin C derivative, ascorbyl glucoside, was questioned for its ability to effectively brighten skin compared to pure vitamin C, which is notoriously unstable. The product's practical pump bottle was noted as a positive feature, but the overall experience was marred by its texture and lack of significant brightening power.





